Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 01 August 2006
Grant from UK gene therapy research
programme
The UK Department of Health has awarded Oxford BioMedica £0.5 million to develop its proprietary LentiVector technology for use in the treatment of single gene inherited disorders
The focus of the work is to be haemophilia A, a condition caused by a defective gene for Factor VIII, a key component of the mechanism for forming blood clots The LentiVector technology, developed primarily for the company's neurotherapy pipeline, can be used in many areas outside the field of neurobiology
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
It is ideally suited to the treatment of single gene disorders where therapy is based on functional correction of a defective gene in patients.
In this situation, there is a need for long-term, stable and predictable gene activity and this can be achieved with the LentiVector technology.
In 2001 the company initiated a programme to develop a product known as Requinate.
Requinate comprises a LentiVector gene delivery system carrying a modified version of the human Factor VIII gene.
During this exploratory programme the company solved several problems that had been encountered by others attempting gene therapy for haemophilia.
However, since haemophilia falls outside of the Company's therapeutic focus of cancer and neurotherapy, the programme has received minimal internal resources.
The new money from the Department of Health will enable the company to progress the Requinate haemophilia programme without compromising progress of its cancer and neurotherapy products.
The current market for Factor VIII treatment is in excess of $1.0 billion.
Commenting on the award, Oxford BioMedica's chief excutive, Alan Kingsman said "We are pleased to see the Department of Health implementing the government's decision to place gene-based medicine in the mainstream of healthcare in the UK.
"We are also delighted to be the only company selected to contribute to this initiative and to aid in the process of bringing products to the market that will directly benefit patients with genetic diseases.
"Oxford BioMedica is currently evaluating how it can expand the application of the LentiVector technology for other inherited disorders, in addition to haemophilia, while retaining its essential focus on bringing its current product pipeline in cancer and neurotherapy to the market as quickly as possible".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
